.svg)
Charco Neurotech
Bringing back smiles for people with Parkinson’s
About the product
Assessment Overview
Foundational criteria clusters
This constitutes the foundational threshold.
Technical aspects
The CUE1 seems reliable and user-friendly, with an app for customisation. The CUE1 utilises pulsed cueing and high-frequency focused vibrotactile stimulation to alleviate symptoms, including slowness, stiffness, rigidity, freezing of gait, and more. This results in improved quality of life for you.
Developed by a team of designers, engineers, and clinicians, the CUE1 offers a novel, non-invasive approach to improving the quality of life for people with Parkinson’s with the simple push of a button. With over 3,000 people using CUE1 daily, pilot tests have seen users with Parkinson’s improve their MDS-UPDRS scores by an average of 7.8 points, considered clinically significant 3.
Clinical utility and safety
Pilot tests and user reports suggest the CUE1's effectiveness. Utilising non-invasive, focused vibrotactile stimulation and cueing to improve movement. A wearable, discreet and adjustable medication reminder and recording system. Track symptoms, progression and quality-of-life measures with the CUE app 3.
Usability and human centricity
The CUE1 has been developed with user feedback and is designed for ease of use and acceptability. It also fosters interaction between patients and healthcare professionals through symptom tracking 3.
Data management
While the CUE1 app likely has a privacy policy, details on data confidentiality, informed consent, and data deletion are not explicitly mentioned 3.
Functionality
The CUE1 has clear features, goals, and customizable interactive elements, making it highly functional for its intended use 3.
Content
The information provided is patient-reviewed and seems credible, but there is no explicit mention of healthcare professional review or evidence-based practice 3.
Endorsement
There is no explicit endorsement by major health organizations or authorities, but the product's reception and use suggest a level of credibility 2 3. CUE1 is available to everyone who needs one, regardless of their financial situation. The company says they are working hard to make CUE1 available on the NHS and through private medical insurance.
Maintenance
The company is actively involved with the Parkinson's community, suggesting ongoing updates and maintenance. To update the CUE1 firmware, please refer to our guide document on the company's website 4.
Developer
Charco Neurotech demonstrates ethical conduct, user engagement, and a commitment to continuous improvement and addressing user needs 4.
Contextual criteria clusters
Emphasizes the tool's integration into specific scenarios.
Data-protection compliance
Compliance with data protection laws is assumed but needs to be explicitly stated 3.
Safety regulatory compliance
The non-invasive nature implies safety, and the company is likely pursuing regulatory approval, but specific certifications are not detailed 2.
Interoperability and data integration
The CUE1 app allows for data tracking, but integration with other systems or EHRs is not specified 3.
Cultural requirements
There is no information on cultural adaptability, such as language or cultural considerations 3.
Affordability
The CUE1 is priced at £295, which may be affordable relative to other Parkinson's interventions, but socioeconomic context is not discussed 2.
Cost-benefit
While the device is less expensive than invasive treatments, a formal cost-benefit analysis is not provided 2.
Implementatability
The CUE1 fits into daily life without additional infrastructure, but its scalability in various healthcare settings is not detailed 3.
.jpeg){kind=avatar}
